CNS Pharmaceuticals Announces US Drug Manufacturing Milestones
03 sept. 2020 08h00 HE
|
CNS Pharmaceuticals, Inc.
Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of...
Potential for Fundamental Change in the Treatment of Brain Cancer
18 oct. 2019 09h13 HE
|
Noxopharm
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international...
Nascent Biotech Has Entered into an Agreement to Perform Phase I Clinical Study for Brain Cancer
19 août 2019 14h04 HE
|
Nascent Biotech, Inc.
Study Planned for Multiple Brain Cancer Types in Phase I Setting San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced they...
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29 juil. 2019 08h00 HE
|
VBI Vaccines, Inc.
— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
04 juin 2019 08h00 HE
|
VBI Vaccines, Inc.
Well tolerated at all doses with no safety signalsThree patients in high dose (10 µg) cohort showed evidence of stable disease by MRI10 µg dose selected for Part B of the study, which is expected...
CCAB announces creation of new brain cancer therapeutic company, Empirica Therapeutics, as part of its strategy to advance new early-stage life sciences companies
20 févr. 2019 10h30 HE
|
Centre for the Commercialization of Antibodies and Biologics
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The Centre for the Commercialization of Antibodies and Biologics (CCAB) today announced a license agreement with Empirica Therapeutics Inc. aimed at...
Candel Therapeutics Completes $28.7 Million Series B Financing
04 janv. 2019 14h33 HE
|
Candel Therapeutics
Proceeds to Accelerate Enrollment of Phase 3 Localized Prostate Cancer Clinical Trial and to Advance Late Stage High-Grade Glioma Clinical Program Candel to Expand Clinical Trials in Other...
Oblato acquires all rights to glioblastoma drug from OMRF
29 oct. 2018 11h21 HE
|
Oklahoma Medical Research Foundation
OKLAHOMA CITY, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Oblato, Inc., has acquired all rights from the Oklahoma Medical Research Foundation to OKN-007, an investigational drug for the treatment of...
National Brain Tumor Society Responds to the 2018 Cancer Progress Report to Congress and the American Public
13 sept. 2018 16h59 HE
|
National Brain Tumor Society
Newton, MA , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Less than two weeks after the unfortunate passing of John McCain as a result of brain cancer, the just-released American Association for Cancer...
National Brain Tumor Society Brings Realities of Glioblastoma to Congress
18 mai 2018 16h57 HE
|
National Brain Tumor Society
Washington, D.C., May 18, 2018 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, held a congressional...